The First Affiliated Hospital of the People's Liberation Army General Hospital, Beijing, People's Republic of China.
Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Onco Targets Ther. 2014 Sep 26;7:1717-22. doi: 10.2147/OTT.S67380. eCollection 2014.
Brentuximab vedotin (SGN-35), an anti-cluster of differentiation (CD)-30 antibody conjugated to the anti-tubulin agent monomethyl auristatin E, has demonstrated promising efficacy and tolerability in relapsed and heavily treated Hodgkin lymphoma (HL). In this study, we report the Asian experience with brentuximab vedotin in patients with relapsed or refractory CD30-positive (CD30+) HL.
This is an observational, multicenter, retrospective study. Between October 2011 and June 2013, a total of 22 patients were treated with brentuximab vedotin under a named patient program in Asia. Patients received a 30 min infusion of brentuximab vedotin at a dose of 1.8 mg/kg of body weight every 3 weeks.
Four patients (18.2%) showed a complete response, and the overall response rate was 72.7%. The median duration of response was 4.4 months (range 1.0-17.4). The median progression-free survival was 5.7 months, and the median overall survival has not yet been reached. The 1-year expected survival rate was 67.2%. The most common grade 3/4 adverse events were neutropenia (n=7; 31.8%). No patients experienced grade 3/4 sensory neuropathy.
These results confirm that brentuximab vedotin as a single agent is also effective and well tolerated when used in Asian patients with relapsed and refractory CD30+ HL.
Brentuximab vedotin（SGN-35）是一种抗分化簇（CD）-30 抗体与抗微管蛋白药物单甲基奥瑞他汀 E 偶联而成的药物，在复发和治疗后复发的霍奇金淋巴瘤（HL）患者中显示出有前景的疗效和耐受性。在这项研究中，我们报告了亚洲患者使用 Brentuximab vedotin 治疗复发或难治性 CD30 阳性（CD30+）HL 的经验。
这是一项观察性、多中心、回顾性研究。在 2011 年 10 月至 2013 年 6 月期间，共有 22 名患者在亚洲接受了 Brentuximab vedotin 的命名患者计划治疗。患者每 3 周接受一次 30 分钟的 Brentuximab vedotin 输注，剂量为 1.8mg/kg 体重。
4 名患者（18.2%）出现完全缓解，总体缓解率为 72.7%。反应持续时间的中位数为 4.4 个月（范围 1.0-17.4）。无进展生存期的中位数为 5.7 个月，总生存期的中位数尚未达到。1 年预期生存率为 67.2%。最常见的 3/4 级不良事件为中性粒细胞减少症（n=7；31.8%）。没有患者发生 3/4 级感觉神经病变。
这些结果证实，Brentuximab vedotin 作为单一药物，在亚洲复发和难治性 CD30+HL 患者中也具有疗效，且耐受性良好。
